Life Sciences Archive » August, 2006

Life Sciences - August, 2006

130 articles

• Appeals Court Rules Invisalign Patents Invalid
• Cerus Settles Class Action, Derivative Lawsuits
• Pioneer Defeats Orthopedic Giant In Patent Case
• FDA Warns On Online Drugs After Fakes Found
• Johnson & Johnson Wins Medical Device Antitrust Suit
• Supreme Court's Obviousness Case Draws 16 Briefs
• Airline, Health Care Lawsuits Fuel Class Action Surge
• Pfizer Gets Setback In Lipitor Patent Battle
• Judge Rejects $50M Award In Vioxx Case
• FDA May Outlaw Over-The-Counter Skin Bleach Products
• Innogenetics Optimistic On HCV Patent Trial
• Schering-Plough Pays Government $435M
• Consumer Activists Press For Stronger Cipro Warning
• Purdue Fends Off Generic OxyContin Competition
• FDA Seizes Infusion Pumps Amid Safety Fears
• After Court Loss, Biotech Company Removes Enzyme
• FDA Rejects EPIX Appeal To Avoid New Trials
• FDA Slammed For Silence On ADHD Warning Labels
• Former Solutia Execs Look To Regain Pension Plans
• California Lawmakers Forge Discount Drug Deal
• Court Suspends Lawyers After $200M Fen-Phen Case
• Biovail Takes Aim At FDA Over Generic Wellbutrin
• Science Companies To Divest After FTC Request
• FDA OKs Over-The-Counter "Morning After" Pill
• Gateway Capital Offers To Fund SeraCare's Ch. 11 Exit
• Lawsuit Filed Over Hemophilia Drug
• Wyeth Premarin Trial Kicks Off
• FDA Looks To Modernize Drug Registration System
• California Discount Drug Deal Draws Ire
• Ausam Secures 90 More Days To File Chapter 11 Plan
• Group Raises Safety Concerns Over Hormone Treatment
• Drug Cos. Put Off Planning For Generic Competition
• Bradley Pharmaceutical Director Steps Down
• Eight Charged In $70M Black-Market Drug Scam
• Nixon Peabody Nets Three IP Attorneys
• Bush Lauds Tougher Access To "Morning After" Pill
• J&J Unit Asserts Bladder Drug Patent Again
• Pfizer Asks Judge To Reconsider Vote Dilution
• Speed Up Drug Seizure Probe, Senator Demands
• Shareholders Seek End To SeraCare Chapter 11 Control
• Hospitals To Pay $151M For Excess Medicaid Payments
• Federal Circuit Overturns Jury Verdict Against ACell
• First Trial Over Prempro Begins For Wyeth
• No End In Sight In Plavix Battle
• Gloves Come Off In Plavix Battle
• Jury Bats Down Synthon's Claim Against Pfizer
• Barr Back In The Ring Over Plan B
• RFID Case Pits Inventor Against Six Corporate Giants
• In Gleevec Feud, Novartis Targets Indian Patent Rules
• DexCom Scores Stay, Partial Dismissal In Abbott Suit
• Investment Firms Offer Loan Deal To SeraCare
• Vioxx User Wins $51 Million Award In Court
• Ranbaxy Bids For Second Look In Lipitor Feud
• Omnicare Exec Charged With Medicaid Fraud
• State Legislators Rally Around Medical Data Technology
• Trial Slated For Monday In Wyeth Hormone Drug Case
• Par Pharmecuticals Stung By Another Suit
• Honeywell $46.58 Million Jury Verdict Overturned
• IP Partner Comes To Dechert By Way Of South Korea
• In HIV/AIDS Fight, Tough Choices Loom For Thailand
• Trends In Compulsory Licenses In Greater China
• Bristol-Myers, Sanofi Try To Cope With Generic Plavix
• FDA Warns Teleflex Over Device Quality Failures
• Shire, Barr Resolve Suits Over Generic Adderall
• FDA Drug Directory Dangerously Incomplete: Report
• Abbott Slashes HIV Drug Price For Developing Nations
• FTC Extends Antitrust Review Of Barr Acquisition
• ZymoGenetics Punches Bristol-Myers With Suit
• Sanofi, Bristol-Myers Fire Back In Plavix Feud
• Orthopedic Cos. Face Antitrust Class Actions
• Novartis Challenges Gleevec Patent Block In India
• Merck And Teva May Forgo Trial Over Actonel
• French Tax Raises Money For Drugs—And IP Concerns
• Pfizer Settlement Torpedoes Quigley Reorganization Plan
• Solvay Sues Canada Co. Over ANDA For Generic Aceon
• The 'Catalona' Decision And The Ownership Of Biological Samples And Clinical Data
• Digene To Pay $3.5M Over 13 Months In License Pact
• Postal Worker Pleads Guilty To Insider-Trading Scheme
• FDA Warns Companies Over Unapproved Drugs
• The Future Of Pay-Or-Play Laws
• Heart-Device Lawsuits Skyrocket For Boston Scientific
• Foley & Lardner Scores New Partner
• Controversial Bill Divides AIDS Organizations
• Glaxo Forks Over $70M in Drug-Pricing Fraud
• Law Firm Profile: Jenner & Block LLP
• Sanofi Sues To Protect Lovenox
• Tyco Off The Hook In Oil-For-Food Probe
• FTC Moves To Stop U.S. Mammogram Monopoly
• Patent Suits Entangle Clinical Trial Tech. Industry
• Barr Moves To Get Plan B To The Market
• J&J Unit Under Scrutiny For Alleged Off-Label Marketing
• Baker & Daniels Nabs Two Biotech Lawyers
• Altana And Wyeth Strike Again Over Protonix
• Apotex Launches At-Risk Generic Plavix
• Medtronic, Others Fall Under Antitrust Scrutiny
• Inventor Falsified Experiment, Federal Circuit Says
• King Pharmaceuticals Reaches $38M Settlement
• Protesters Target GSK Over HIV Drug Patent
• Pharma Exec To Pay $20M Over Illegal Bonus
• Governors Push FDA For Guidance On Biotech Generics
• Reactions Mixed To Latest Senate Patent Reform Bill
• Health Exec Eyes Generic Plavix On The Horizon
• Eisai Sues To Protect Popular Alzheimer's Treatment
• Claims Tossed In Suit Against Biotech Company
• KCI Wound-Healing Patent Not Infringed, Judge Rules
• Howrey Loses Renowned IP Chair
• Tyco's Patent Counterclaims Ordered Into New Case
• Medtronic Wins Patent Fight Over Sinus Surgery Tool
• Apotex Loses Battle With Daiichi Over Ear-Drop Patent
• SeraCare Wins Another Extension Of Exclusive Period
• Ausam Battles Keryx Over Share Losses
• Amgen Gets Mixed Ruling In Patent Fight
• Fifth Vioxx Victory Bodes Well For Merck
• Anti-Kickback Rules Changed To Allow Computer Donations
• Court Hands Pfizer Mixed Results In Lipitor Battle
• Biovail Suffers One-Two Punch In Wellbutrin XL Feud
• Novo Nordisk Sues Pfizer Over Insulin Patent
• Mylan's ANDA Raises Sankyo's Blood Pressure
• Abbott And Teva Settle Fight Over Biaxin
• Canada Takes Aim At Biovail Chair In Trading Probe
• Plavix Patent Litigation to Resume, Sanofi Exec Says
• Warner Chilcott Sues To Protect Contraceptive Drug
• Judge OKs Aphton Sale Of Cancer Drug
• SEC Puts Impath Fraud To Rest With $2M Settlement
• Drug Cos. Hit With Plavix Antitrust Class Action
• Second Federal Trial Over Vioxx Begins
• Van der Moolen Trader Acquitted Of Front-Running
• New Report Casts Doubt On PhRMA Study
• Whistleblower Challenges $40M Medtronic Settlement
• U.S. Surgeon General Exits With Little Fanfare